Current stock page

Stock Analysis

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis

Madrigal Pharmaceuticals, Inc. (MDGL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

MDGL Stock Analysis Summary

Madrigal Pharmaceuticals, Inc. (MDGL) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 67/100. Momentum is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

MDGL at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$427.39
AIQ Score57/100
Overall ViewNeutral
Technical Analysis ConsensusSell
Market Cap$12.5B
P/E Ratio (TTM)-72.32
Forward P/E—
EPS (Q3 FY2026)$1.90
Revenue (Q3 FY2026)$431.27M
Dividend Yield (TTM)0.00%
Beta0.41
Volume441.25K
52-week range$353.54-$615.00
RSI 1442.45
50-Day SMA$475.72
200-Day SMA$496.00
Analyst Price Target$660.50
Next EarningsFeb 18, 2027
As of Nov 13, 2026 · Market close

MDGLMadrigal Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$427.39+$2.18 (+0.51%)

Latest quote

  • Momentum
    40
  • Value
    66
  • Quality
    67
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

MDGL Stock Analysis Summary

Madrigal Pharmaceuticals, Inc. (MDGL) currently has an AIQ Score of 57/100, indicating a neutral setup. Quality is the strongest factor at 67/100. Momentum is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, MDGL has AIQ Score of 57/100 with Quality base of 67/100 and fading Momentum at 40/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (67/100) leads while Momentum (40/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.51% stock move · MDGL classified in Biotechnology.

Current Evidence

NeutralMDGL is in a neutral AIQ regime; Quality is the strongest visible factor at 67/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is MDGL Bullish or Bearish Right Now?

MDGL currently has a neutral overall setup. Quality is the strongest factor at 67/100, while Momentum is weakest at 40/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 67/100.
  • - Analyst target implies +54.54% upside from the latest quote.
Bear Case
  • - Momentum is weak at 40/100.
  • - Price is -13.83% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (25 vs 14).

Current Consensus

MDGL's Technical Analysis Consensus is currently Sell, with 14 buy, 7 neutral, and 25 sell votes. MDGL's 14-day RSI is 42.45, which places the stock in a weaker momentum range. MDGL's beta is 0.41, indicating lower market sensitivity than the broad market.

Signal Confidence
Moderate agreement

What Changed in MDGL?

The largest recent change in MDGL is Momentum moving down by 1.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+0.0
Momentum
-1.0
Quality
+1.0
Risk
-1.0

What Would Change the MDGL Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

MDGL Decision Framework

Public evidence layers, setup checks, and risk context for Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis

Madrigal Pharmaceuticals, Inc. has an AIQ Score of 57/100 in a Neutral regime. Quality is strongest at 67/100. Beta is 0.41, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextMDGL is in a Neutral AIQ regime with score 57/100.
Signal ConflictThe primary conflict is that quality leads at 67/100 while momentum lags at 40/100.
Factor EvidenceMomentum 40/100 · Value 66/100 · Quality 67/100 · Risk 63/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 67/100.

TimingFail

Momentum is 40/100 and RSI (14) is 42.5.

Regime fitWait

MDGL is in a Neutral regime at 57/100.

Risk controlWait

Risk factor is 63/100 with beta 0.41 and annual volatility 42.57%.

ConflictWait

Current conflict: quality leads at 67/100 while momentum lags at 40/100.

AIQ Score
57/100
Price
$427.39
Beta
0.41
RSI (14)
42.5

MDGL Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

MDGL Fundamentals

MDGL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$431.27M
Net income
$55.44M
Free cash flow
$116.63M
View full MDGL fundamental analysis

MDGL Technical Analysis

MDGL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
42.45
Price vs SMA-50
-10.16%
View full MDGL technical analysis

MDGL Stock Catalysts

Track MDGL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 18, 2027
Analyst target
$660.50
News items
4
View MDGL earnings and stock catalysts

MDGL Dividend Analysis

MDGL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View MDGL dividend history and analysis

MDGL Financial Data

MDGL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$431.27M
EPS
$1.90
Periods
8
View MDGL financials

MDGL Risk Analysis

MDGL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.41
Risk score
63/100
1Y volatility
42.57%
View MDGL risk analysis

MDGL Stock News

MDGL stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read MDGL stock news

MDGL vs Biotechnology Peers

Current peer cohort: MDGL · MIRM · MLYS · NAMS · NBIX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
MDGL
Current stock
57/10066/10040/10063/100-0.3242.57%Current
MIRM
Mirum Pharmaceuticals, Inc.
53/10057/10054/10051/1000.7948.60%MDGL vs MIRM
MLYS
Mineralys Therapeutics, Inc.
33/100—23/10035/100-1.4861.66%MDGL vs MLYS
NAMS
NewAmsterdam Pharma Company N.V.
41/10042/10022/10048/100-0.9153.82%MDGL vs NAMS
NBIX
Neurocrine Biosciences, Inc.
74/10077/10070/10069/1000.4935.22%MDGL vs NBIX
Pairwise Compare links: MIRM · MLYS · NAMS · NBIXMDGL vs MIRMMDGL vs MLYSMDGL vs NAMSMDGL vs NBIXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a MDGL stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for MDGL: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-72.32
As of Nov 13, 2026
Revenue growth
50.13%
Gross margin
90.96%
Current debt / equity
0.56
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$431.27M
Quarter net income
$55.44M
Quarter free cash flow
$116.63M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
42.45
MACD
-14.34

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
63/100
Beta
0.41
Annual volatility
42.57%
Max drawdown
-34.26%

MDGL Stock FAQ

What is MDGL stock price today?

Madrigal Pharmaceuticals, Inc.'s current stock price is $427.39. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is MDGL bullish or bearish right now?

MDGL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is MDGL's market cap?

MDGL's market cap is $12.5B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is MDGL's current P/E ratio?

MDGL's current P/E ratio is -72.32 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is MDGL's RSI?

MDGL's 14-day RSI is 42.45 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is MDGL above its 50-day and 200-day moving averages?

MDGL is -10.16% from its 50-day SMA and -13.83% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is MDGL's next earnings date?

MDGL's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does MDGL pay a dividend?

MDGL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.